Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4444463 | 0.98 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30810811 | 0.98 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| Lithium SCHEMBL30810804 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28379424 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| Ethane SCHEMBL27774044 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL2154353 | 0.96 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3410859 | 0.87 | CA1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29591833 | 0.84 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL49810 | 0.84 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4349591 | 0.84 | CA1 (0.44) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707553-B2 | P-chirogenic organophosphorus compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-18 | — | — | US | disclosed |
| EP-3150613-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-04-05 | — | — | EP | disclosed |
| EP-2731956-B1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20160023199-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | SYNTHELOR SAS (FR) | 2016-01-28 | — | — | US | disclosed |
| US-9186661-B2 | P-chirogenic organophosphorus compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2015-11-17 | — | — | US | disclosed |
| US-20140142325-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2014-05-22 | — | — | US | disclosed |
| EP-2731956-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-8404915-B2 | 1) at least one diaryl-substituted diphosphine ligand; 2) a chromium metal precursor; and 3) optionally, one or more activators | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2013007724-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-01-17 | — | — | WO | disclosed |
| US-20080058486-A1 | Phosphine Ligand-Metal Compositions, Complexes, and Catalysts For Ethylene Trimerizations | SYMYX TECHNOLOGIES INC. | 2008-03-06 | — | — | US | disclosed |
| US-20040133042-A1 | Diphosphines | BROWN JOHN MICHAEL (GB) | 2004-07-08 | — | — | US | disclosed |
| US-6706926-B1 | ENANTIOSELECTIVE HYDROGENATION CATALYSTS | ISIS INNOVATION LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| EP-1124833-B1 | DIPHOSPHINES | ISIS INNOVATION (GB) | 2003-01-08 | — | — | EP | disclosed |
| EP-1124833-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026220-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133042-A1 | Diphosphines | SIGMAR1, SSR4, LBR | CA1 3498/4885CA2 1516/4885CA7 3142/4885 |
| US-20160023199-A1 | P-CHIROGENIC ORGANOPHOSPHORUS COMPOUNDS | ACHE, PTMS, DDT | CA1 102/4885CA2 27/4885CA7 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.